1. 尊龙凯时 - 人生就是搏!

      Pipeline

      R&D PIPELINE

      We established a diversified and comprehensive R&D pipeline covering oncology, autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, ophthalmology, etc.

      Major R&D Pipelines

      • 18

        New Molecular Entity drugs marketed in China

      • 4

        Other innovative drugs marketed in China

      • 90

        +

        In-House Innovative Pharmaceuticals under Clinical Development

      • ~

        400

        Ongoing Clinical Studies       

      • 20

        +

        Ongoing International Clinical Studies

      *By January 6, 2025

      Oncology
      临床前
      Phase I
      Phase II
      • HRS-4357

        PSMA Nuclear Medicine

        Metastatic castration-resistant prostate cancer
        Single Agent

        Phase II

      • HRS-1167

        PARP1

        Recurrent ovarian cancer
        Combination Therapy (bevacizumab)

        Phase II

        Advanced prostate cancer
        Combination Therapy

        Phase II

        Advanced solid tumors
        Single Agent

        Phase I

      • SHR-4602

        HER2 ADC (Next-gen)

        HER2-expressing or -mutated advanced solid tumors
        Combination Therapy

        Phase II

        HER2-expressing or -mutated solid tumors
        Single Agent

        Phase I

      • SHR-1501

        IL-15

        Non-muscle invasive bladder cancer
        Combination Therapy (BCG bladder perfusion)

        Phase II

      • SHR-A1912

        CD79b ADC

        B-cell non-Hodgkin lymphoma
        Combination Therapy

        Phase II

        B-cell non-Hodgkin lymphoma
        Single Agent

        Phase I
        US

        B-cell lymphoma
        Single Agent

        Phase I

      • HRS2398

        ATR

        Advanced solid tumors
        Combination Therapy

        Phase II

      • HRS-8080

        SERD

        ER-positive, HER2-negative unresectable or metastatic breast cancer
        Combination Therapy (dalpiciclib)

        Phase II

        Advanced breast cancer
        Single Agent/Combination Therapy

        Phase I

      • HRS-4642

        KRAS G12D

        Advanced solid tumors with KRAS G12D mutations
        Combination Therapy

        Phase II

        Advanced solid tumors
        Single Agent

        Phase I

      • HRS-6209

        CDK4

        Advanced breast cancer
        Combination Therapy (HRS-8080/HRS-1358)

        Phase II

        Advanced solid tumors
        Single Agent

        Phase I

      • SHR-9839

        Advanced solid tumors
        Combination Therapy

        Phase II

        Advanced solid tumors
        Single Agent

        Phase I

      • HRS-2189

        KAT6

        Advanced breast cancer
        Combination Therapy

        Phase II

        Advanced malignant tumors
        Single Agent

        Phase I

      • HRS-5041

        AR-PROTAC

        Advanced prostate cancer
        Combination Therapy

        Phase II

        Metastatic castration-resistant prostate cancer
        Single Agent

        Phase I
        Australia, China

      • SHR-1826

        c-Met ADC

        Advanced solid tumors
        Combination Therapy

        Phase II

        Advanced malignant solid tumors
        Single Agent

        Phase I

      Phase III
      • SHR-A2009

        HER3 ADC

        EGFR-mutated advanced or metastatic non-small cell lung cancer that has failed EGFR TK therapy
        Single Agent

        Phase III

        Advanced solid tumors
        Combination Therapy

        Phase II

        Advanced or metastatic solid tumors
        Single Agent

        Phase I

        Advanced solid tumors
        Single Agent

        Phase I
        Japan and Korea

      • SHR-A1921

        TROP2 ADC

        Platinum-sensitive recurrent epithelial ovarian cancer
        Single Agent or Combination Therapy with carboplatin

        Phase III

        Platinum-resistant recurrent epithelial ovarian cancer
        Single Agent

        Phase III

        Advanced solid tumors
        Single Agent

        Phase II
        US, Australia

        Advanced solid tumors
        Combination Therapy

        Phase II

      • SHR-A1904

        Claudin 18.2 ADC

        2nd-line CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma
        Single Agent

        Phase III

        CLDN18.2-positive advanced solid tumors
        Combination Therapy (adebrelimab)

        Phase III

        Advanced pancreatic cancer
        Single Agent

        Phase I

        Advanced solid tumors
        Single Agent

        Phase I
        US, Australia, China

      • SHR-A2102

        Nectin-4 ADC

        2nd/3rd-line locally advanced or metastatic urothelial carcinoma
        Single Agent

        Phase III

        Advanced solid tumors
        Single Agent

        Phase II
        US

        Advanced gynecologic malignancies
        Single Agent

        Phase II

        Locally advanced or metastatic non-small cell lung cancer
        Combination Therapy

        Phase II

        Advanced urothelial carcinoma
        Combination Therapy (adebrelimab)

        Phase II

        Locally advanced or metastatic esophageal cancer
        Combination Therapy (adebrelimab)

        Phase II

        Advanced solid tumors
        Single Agent

        Phase I

      NDA/BLA Filed
      • SHR2554

        EZH2

        Relapsed and refractory peripheral T-cell lymphoma
        Single Agent

        NDA/BLA Filed

        T-cell lymphoma
        Combination Therapy

        Phase II

        Relapsed and refractory follicular lymphoma
        Single Agent

        Phase II

        Refractory/relapsed T-cell lymphoma
        Single Agent

        Phase I

      • SHR-1701

        PD-L1/TGF-β

        1st-line advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer
        Combination Therapy (chemotherapy)

        NDA/BLA Filed

        Advanced solid tumors
        Single Agent

        Phase I
        Australia

      • SHR-A1811

        HER2 ADC

        2nd-line and subsequent locally advanced or metastatic HER2-mutated adult non-small cell lung cancer
        Single Agent

        NDA/BLA Filed

        HER2-positive metastatic breast cancer
        Single Agent

        Phase III

        HER2-low recurrent/metastatic breast cancer
        Single Agent

        Phase III

        Adjuvant therapy for HER2-positive breast cancer
        Single Agent

        Phase III

        HER2-positive recurrent or metastatic breast cancer
        Combination Therapy

        Phase III

        3rd-line HER2-positive advanced colorectal cancer
        Single Agent

        Phase III

        1st-line treatment for HER2-mutated advanced or metastatic non-small cell lung cancer
        Single Agent

        Phase III

        Advanced solid tumors with HER2 expression
        Combination Therapy (fuzuloparib)

        Phase II

        HER2-low metastatic or unresectable breast cancer
        Combination Therapy

        Phase II

        HER2-expressing gynecological malignancies
        Single Agent

        Phase II

        HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
        Combination Therapy (adebrelimab+chemotherapy)

        Phase II

        1st-line HER2 mutated, amplified, or overexpressed advanced non-small cell lung cancer
        Combination Therapy (pyrotinib/adebrelimab)

        Phase II

        Locally advanced unresectable or recurrent metastatic biliary tract cancer with HER2 expression/amplification
        Single Agent

        Phase II

        Gastric cancer or adenocarcinoma of the gastroesophageal junction and colorectal cancer
        Single Agent

        Phase I

        Advanced solid tumors
        Single Agent

        Phase I
        US, Australia, Asia Pacific (including China)

      • HR20013

        NK-1RA in combination with 5-HT3RA

        Prevention of highly emetogenic chemotherapy-induced nausea and vomiting
        Single Agent (FDC)

        NDA/BLA Filed

        Prevention of nausea and vomiting caused by antineoplastic drugs with moderate risk of vomiting
        Single Agent (FDC)

        Phase III

      Marketed
      • Apatinib

        VEGFR

        HER2-negative metastatic breast cancer adult patients with germline BRCA mutations
        Combination Therapy (fuzuloparib)

        Marketed

        Advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressed or relapsed after at least 2Ls of systematic chemotherapy
        Single Agent

        Marketed

        Advanced hepatocellular carcinoma failed or intolerable after at least first-line systemic therapy
        Single Agent

        Marketed

        1st-line unresectable or metastatic hepatocellular carcinoma
        Combination Therapy (camrelizumab)

        Marketed

        1st-line unresectable or metastatic hepatocellular carcinoma
        Combination Therapy (camrelizumab)

        NDA/BLA Filed
        US, Europe, and Asia Pacific (including China)

        Unresectable hepatocellular carcinoma
        Combination Therapy (TACE+camrelizumab)

        Phase III

      • Pyrotinib

        HER1, HER2, and HER4

        Relapsed or metastatic advanced HER2-positive breast cancer patients without previous HER2 treatment
        Combination Therapy (trastuzumab+docetaxel)

        Marketed

        Relapsed or metastatic HER2-positive breast cancer with previous trastuzumab treatment
        Combination Therapy (capecitabine)

        Marketed

        Neoadjuvant treatment for early or locally advanced HER2-positive breast cancer
        Combination Therapy (trastuzumab+docetaxel)

        Marketed

        Extended adjuvant therapy for HER2-positive breast cancer
        Single Agent

        Phase III

        Advanced non-squamous non-small cell lung cancer with HER2 mutation
        Single Agent

        Phase III
        US, Europe, and Asia Pacific (including China)

      • Camrelizumab

        PD-1

        Relapsed and refractory classical Hodgkin lymphoma after at least two systematic therapies
        Single Agent

        Marketed

        Advanced hepatocellular carcinoma after sorafenib and/or lenvatinib and/or oxaliplatin-containing chemotherapy treatments
        Single Agent

        Marketed

        1st-line unresectable locally advanced or metastatic EGFR-mut negative ALK-negative NSCLC
        Combination Therapy (pemetrexed+carboplatin)

        Marketed

        Locally advanced or metastatic esophageal adenocarcinoma progressed after or intolerable to 1st-line treatment
        Single Agent

        Marketed

        Advanced nasopharyngeal carcinoma progressed after or intolerable to 2nd-line+ chemotherapy
        Single Agent

        Marketed

        1st-line locally relapsed or metastatic nasopharyngeal carcinoma
        Combination Therapy (cisplatin+gemcitabine)

        Marketed

        1st-line unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma
        Combination Therapy (cisplatin+paclitaxel)

        Marketed

        1st-line locally advanced/metastatic squamous non-small cell lung cancer
        Combination Therapy (carboplatin+paclitaxel)

        Marketed

        1st-line unresectable or metastatic hepatocellular carcinoma
        Combination Therapy (apatinib)

        Marketed

        Recurrent metastatic cervical cancer
        Combination Therapy (famitinib)

        NDA/BLA Filed

        1st-line advanced hepatocellular carcinoma
        Combination Therapy (apatinib)

        NDA/BLA Filed
        US, Europe, and Asia Pacific (including China)

        Relapsed and refractory classical Hodgkin lymphoma
        Single Agent

        Phase III

        Unresectable hepatocellular carcinoma
        Combination Therapy (TACE+apatinib)

        Phase III

        Unresectable locally advanced esophageal cancer
        Combination Therapy

        Phase III

        1st-line advanced cervical cancer
        Combination Therapy (famitinib)

        Phase III

      • fuzuloparib

        PARP1/2

        Maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieve complete or partial remission with 1st-line platinum-based chemotherapy
        Single Agent

        Marketed

        Metastatic HER2-negative breast cancer with BRCA1/2 mutation
        Single Agent/Combination Therapy (apatinib)

        Marketed

        Recurrent platinum-sensitive gBRCA-mut ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after 2nd-line+ chemotherapy
        Single Agent

        Marketed

        Maintenance therapy for platinum-sensitive recurrent epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma after platinum-containing chemotherapy
        Single Agent

        Marketed

        Metastatic castration-resistant prostate cancer
        Combination Therapy (abiraterone)

        Phase III
        US, Europe, and Asia Pacific (including China)

      • Dalpiciclib

        CDK4/6

        Relapsed or metastatic HR-positive HER2-negative breast cancer progressed after endocrine therapy
        Combination Therapy (fulvestrant)

        Marketed

        Initial endocrine therapy for locally advanced or metastatic HR-positive HER2-negative breast cancer
        Combination Therapy (aromatase inhibitor)

        Marketed

        Adjuvant therapy for HR-positive, HER2-negative breast cancer
        Combination Therapy

        Phase III

      • Rezvilutamide

        AR

        Metastatic hormone sensitive prostate cancer (mHSPC) with high tumor burden
        Single Agent

        Marketed

        Metastatic hormone-sensitive prostate cancer
        Single Agent

        Phase III
        Europe, China

      • Adebrelimab

        PD-L1

        1st-line extensive stage small cell lung cancer (ES-SCLC)
        Combination Therapy (carboplatin + etoposide)

        Marketed

        1st-line therapy for limited-stage small cell lung cancer
        Combination Therapy

        Phase III

        Perioperative treatment of resectable stage II or III non-small cell lung cancer
        Combination Therapy

        Phase III

        1st-line therapy for STK11/KEAP1/KRAS mutated advanced or metastatic non-squamous non-small cell lung cancer
        Combination Therapy (SHR-8068+platinum-containing doublet chemotherapy)

        Phase III

        Advanced hepatocellular carcinoma
        Combination Therapy (SHR-8068+bevacizumab)

        Phase III

        Advanced non-small cell lung cancer
        Combination Therapy (SHR-8068+platinum-containing chemotherapy)

        Phase II

        1st-line advanced biliary tract cancer
        Combination Therapy (SHR-8068+platinum-containing chemotherapy)

        Phase II

        Advanced gastric cancer and esophageal cancer
        Combination Therapy (SHR-8068+platinum-containing chemotherapy)

        Phase II

        Locally advanced cervical cancer
        Combination Therapy

        Phase II

      • Hetrombopag

        TPO-R

        Adult chronic primary immune thrombocytopenia who have not responded well to glucocorticoids, immunoglobulins, etc
        Single Agent

        Marketed

        Severe aplastic anemia who do not respond well to immunosuppressive therapy
        Single Agent

        Marketed

        Primary treatment of severe aplastic anemia
        Combination Therapy

        NDA/BLA Filed

        Chemotherapy-induced thrombocytopenia
        Single Agent

        Phase III
        US, Australia, Europe, and China

        Children with immune thrombocytopenia (ITP)
        Single Agent

        Phase III

        Chronic liver disease with thrombocytopenia with invasive procedures or surgeries
        Single Agent

        Phase III

        Primary treatment of non-severe aplastic anemia
        Combination therapy

        Phase II

      • Linperlisib

        PI3Kδ

        Refractory/relapsed follicular lymphoma in adult patients after 2nd-line+ systematic treatment
        Single Agent

        Marketed

      • Mecapegfilgrastim

        G-CSF

        Chemotherapy-induced neutropenia in adults with malignant cancers
        Single Agent

        Marketed

      Metabolic And Cardiovascular Diseases
      临床前
      Phase I
      Phase II
      • SHR-3167

        Diabetes mellitus
        Single Agent

        Phase II

      • SHR-2004

        FXI

        Prevention of venous thromboembolism after knee arthroplasty
        Single Agent

        Phase II

        Prevention of postoperative venous thromboembolism in patients undergoing ovarian cancer surgery
        Single Agent

        Phase II

        Prevent the risk of stroke or systemic embolism in patients with ventricular fibrillation
        Single Agent

        Phase I

      • HRS-1893

        Obstructive hypertrophic cardiomyopathy
        Single Agent

        Phase II

      • HRS-1780

        Mineralocorticoid receptors

        Chronic kidney disease
        Single Agent

        Phase II

      Phase III
      • INS068

        Insulin

        Type 2 diabetes mellitus
        Single Agent

        Phase III

      • HR17031

        Insulin/GLP-1

        Type 2 diabetes mellitus
        Single Agent (FDC)

        Phase III

      • HRS-7535

        GLP-1 (oral)

        Type 2 diabetes mellitus
        Single Agent

        Phase III

        Overweight or obesity
        Single Agent

        Phase II

        Diabetic kidney disease
        Single Agent

        Phase II

      • HRS9531

        GLP-1/GIP

        Overweight or obesity
        Single Agent

        Phase III

        Type 2 diabetes mellitus
        Single Agent

        Phase III

        Obesity with heart failure
        Single Agent

        Phase II

        Obesity with obstructive sleep apnea
        Single Agent

        Phase II

        Obesity with polycystic ovary syndrome
        Single Agent

        Phase II

        Weight management and type 2 diabetes mellitus
        Single Agent (tablet)

        Phase I

      • SHR-1918

        ANGPTL3

        Homozygous familial hypercholesterolemia
        Single Agent

        Phase III

        Hyperlipidemia
        Single Agent

        Phase II

      • SHR4640

        URAT1

        Primary gout with hyperuricemia
        Single Agent

        Phase III

        Hyperuricemia in patients with gout
        Combination Therapy (febuxostat)

        Phase II

      • SHR6508

        CaSR

        Secondary hyperparathyroidism in patients on maintenance hemodialysis with chronic kidney disease
        Single Agent

        Phase III

      NDA/BLA Filed
      Marketed
      • Henagliflozin

        SGLT-2

        Type 2 diabetes mellitus
        Combination Therapy (metformin+retagliptin)

        Marketed

        Improve glycemic control in adults with type 2 diabetes mellitus
        Single Agent/Combination Therapy (metformin)

        Marketed

        Chronic kidney disease
        Single Agent

        Phase II

      • Retagliptin

        DPP-IV

        Type 2 diabetes mellitus
        Single Agent/Combination Therapy (metformin)

        Marketed

      • Recaticimab

        PCSK9

        Adults with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia who are unable to achieve low-density lipoprotein cholesterol (LDL-C) goals despite moderate or higher doses of statins, or in combination with statins and other lipid-lowering therapies on the basis of dietary control; or as a single agent Adult patients with nonfamilial hypercholesterolemia and mixed dyslipidemia to reduce low-density lipoprotein cholesterol (
        Single Agent

        Marketed

      Immunological And Respiratory Diseases
      临床前
      Phase I
      • HRS-7085

        Inflammatory bowel disease (healthy volunteers)
        Single Agent

        Phase I
        Australia

        Inflammatory bowel disease
        Single Agent

        Phase I

      • HRS-9821

        PDE3/4

        Chronic obstructive pulmonary disease (COPD)
        Single Agent

        Phase I

      • RSS0343

        Non-cystic fibrosis bronchiectasis
        Single Agent

        Phase I

      • SHR-4597

        Asthma
        Single Agent

        Phase I

      • HRS-9813

        Idiopathic pulmonary fibrosis
        Single Agent

        Phase I

      • RSS0393

        Psoriasis
        Single Agent

        Phase I

      • SHR-1139

        Psoriasis
        Single Agent

        Phase I

      • SHR-2173

        Systematic lupus erythematosis
        Single Agent

        Phase I

      Phase II
      • SHR-1905

        TSLP

        Asthma
        Single Agent

        Phase II

        Chronic rhinosinusitis with nasal polyp (CRSwNP)
        Single Agent

        Phase II

        Chronic obstructive pulmonary disease
        Single Agent

        Phase I

        Asthma (healthy volunteers)
        Single Agent

        Phase I
        Australia

      Phase III
      • SHR-1819

        IL-4Rα

        Atopic dermatitis
        Single Agent

        Phase III

        Prurigo nodularis
        Single Agent

        Phase III

        Chronic spontaneous urticaria
        Single Agent

        Phase II

        Atopic dermatitis in children/adolescents
        Single Agent

        Phase I

        Atopic dermatitis (healthy volunteers)
        Single Agent

        Phase I
        China, Australia

      • SHR-1703

        IL-5

        Eosinophilic asthma
        Single Agent

        Phase III

        Eosinophilic granulomatosis with polyangiitis
        Single Agent

        Phase III

      • HRS-5965

        Factor B

        Untreated paroxysmal nocturnal hemoglobinuria
        Single Agent

        Phase III

        Paroxysmal nocturnal hemoglobinuria treated with C5 antibody
        Single Agent

        Phase III

        IgA nephropathy
        Single Agent

        Phase II

      NDA/BLA Filed
      • SHR0302

        JAK1

        Ankylosing spondylitis
        Single Agent

        NDA/BLA Filed

        Moderate-to-severe active rheumatoid arthritis
        Single Agent

        NDA/BLA Filed

        Moderate-to-severe atopic dermatitis
        Single Agent

        NDA/BLA Filed
        China, Canada

        Alopecia
        Single Agent

        NDA/BLA Filed

        Psoriatic arthritis
        Single Agent

        Phase III

        Active radiologically negative mid-axis spondyloarthritis
        Single Agent

        Phase III

        Mild-to-moderate atopic dermatitis
        Single Agent (ointment)

        Phase III

        Ulcerative colitis
        Single Agent

        Phase III
        US, Europe, China

        Vitiligo
        Single Agent (alkaline gel)

        Phase I

      Marketed
      • Vunakizumab

        IL-17A

        Adults with moderate to severe plaque psoriasis who are receiving systemic therapy or phototherapy
        Single Agent

        Marketed

        Active ankylosing spondylitis in adults
        Single Agent

        NDA/BLA Filed

        Moderate-to-severe chronic plaque psoriasis in children and adolescents
        Single Agent

        Phase III

        Psoriatic arthritis
        Single Agent

        Phase III

      • Imrecoxib

        COX2

        Osteoarthritis-related pain
        Single Agent

        Marketed

      Neuroscience
      临床前
      Phase I
      Phase II
      • SHR-1707

        A-beta

        Alzheimer's disease
        Single Agent

        Phase II

        Alzheimer's disease
        Single Agent

        Phase I
        Australia

      • HRS8179

        SUR1

        Severe cerebral edema after massive ischemic stroke
        Single Agent

        Phase II

      • HRS-9231

        MRI of the brain and whole body
        Single Agent

        Phase II

        MRI testing
        Single Agent

        Phase I
        Australia

      Phase III
      NDA/BLA Filed
      Marketed
      • Tegileridine fumarate

        MOR

        Post-operative analgesia for abdominal surgeries
        Single Agent

        Marketed

        Moderate to severe pain after orthopedic surgery
        Single Agent

        NDA/BLA Filed

      • Remimazolam

        GABAa

        Sedation and anesthesia in non-endotracheal intubation procedures/procedures, general anesthesia induction and maintenance
        Single Agent

        Marketed

        ICU sedation with mechanical ventilation
        Single Agent

        Phase III

      Anti-infection
      临床前
      Phase I
      Phase II
      Phase III
      NDA/BLA Filed
      Marketed
      Others
      临床前
      Phase I
      • HRS-2183

        Severe infections caused by gram-negative bacteria
        Single Agent

        Phase I

      Phase II
      Phase III
      NDA/BLA Filed
      Marketed